Diagnostic and Therapeutic Radiopharmaceutical Agents for Selective Discrimination of Prostate Cancer

doi 10.21236/ada484303
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Toward Isozyme-Selective Inhibitors of Histone Deacetylase as Therapeutic Agents for the Treatment of Cancer

Pharmaceutical patent analyst
MedicineDrug DiscoveryPharmaceutical Science
2012English

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen in a Micrometastatic Model of Prostate Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Prostate-Specific Membrane Antigen From Diagnostic to Therapeutic Target: Radionuclide Therapy Comes of Age in Prostate Cancer

BJU International
Urology
2017English

Functional Imaging for Prostate Cancer: Therapeutic Implications

Seminars in Nuclear Medicine
Nuclear MedicineRadiologyImaging
2012English

Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic

Frontiers in Pharmacology
Pharmacology
2020English

How to Achieve Approval of Radiolabeled-Psma Diagnostic and Therapeutic Agents

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

HMGB1: A Promising Therapeutic Target for Prostate Cancer

Prostate Cancer
Cancer ResearchOncologyUrology
2013English

Modernizing the Diagnostic and Decision-Making Pathway for Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Diagnostic Ability of %P2PSA and Prostate Health Index for Aggressive Prostate Cancer: A Meta-Analysis

Scientific Reports
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy